Lupin Ltd

The company's product is a bioequivalent version of Farxiga and will be marketed for indications as per the approved labeling. Dapagliflozin is indicated for the treatment of conditions including Type 2 Diabetes and certain cardiovascular and renal disorders. The launch marks Lupin's continued expansion in the US generics market and strengthens its presence in the oral anti-diabetic segment. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025. Shares of Lupin shed 0.88% to currently trade at Rs 2,312.10 on the BSE.

The approval covers multiple strengths, including 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg, as per the company's regulatory filing dated April 8. The company has also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets (2.5 mg/1,000 mg). The approved product is bioequivalent to Xigduo XR and will be used for the same indications as per the approved label. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025. Shares of Lupin shed 0.35% to Rs 2,285.60 on the BSE.

Lupin has granted 6,495 stock options under ESOP on 09 April 2026.

Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg. The company also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 2.5 mg/1,000 mg. The U.S. FDA has approved Lupin's Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets as bioequivalent to Xigduo' XR for the indications in the approved labeling.

Lupin Ltd is down for a fifth straight session today. The stock is quoting at Rs 2255.6, down 0.83% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.67% on the day, quoting at 22864.2. The Sensex is at 73776.78, up 0.62%.Lupin Ltd has lost around 2.06% in last one month.Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has eased around 5.19% in last one month and is currently quoting at 21808.4, down 0.3% on the day. The volume in the stock stood at 4.95 lakh shares today, compared to the daily average of 10.47 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 2262.4, down 0.08% on the day. Lupin Ltd jumped 17.29% in last one year as compared to a 3.17% rally in NIFTY and a 8.74% spurt in the Nifty Pharma index.The PE of the stock is 18.82 based on TTM earnings ending December 25.

Lupin announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). The acquisition represents a significant milestone in Lupin's strategy to expand its specialty care portfolio and strengthen its presence in Europe. The integration of VISUfarma has significantly expanded Lupin's ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma's strong commercial footprint across key European markets, including Italy, the UK, Spain, Germany, and France, is strengthened by a highly experienced team with deep ophthalmology expertise, trusted relationships, and strong local market insight. VISUfarma enhances Lupin's ability to address the growing global demand for innovative eye care solutions, driven by an ageing population and the growing burden of diabetes-related eye complications.

The approval covers strengths of 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in single-dose vials, the company said in a statement. The product has been deemed bioequivalent to Merck & Co.'s Bridion Injection. It is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged two years and above undergoing surgery. Tentative approval indicates that the drug meets all regulatory requirements but cannot be marketed in the United States until the expiry of applicable exclusivities or patents. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

The approval covers strengths of 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in single-dose vials, the company said in a statement. The product has been deemed bioequivalent to Merck & Co.'s Bridion Injection. It is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged two years and above undergoing surgery. Tentative approval indicates that the drug meets all regulatory requirements but cannot be marketed in the United States until the expiry of applicable exclusivities or patents. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025. The counter shed 0.95% to end at Rs 2,312.70 on the BSE. Powered by Capital Market - Live

Lupin announced that Multicare Pharmaceuticals Philippines, Inc. (MPPI), a subsidiary of Nanomi B.V., the Netherlands (Nanomi), which is a wholly owned subsidiary of the Company, has bought back 2,813,811 equity shares from some of its existing shareholders. Nanomi did not participate in the said buyback. This has resulted in increase in the shareholding of Nanomi in MPPI from 51% to 56.28% effective today.Powered by Capital Market - Live

Pitolisant is indicated for the treatment of excessive daytime sleepiness in patients suffering from narcolepsy, including adults and children aged six years and above. It is also used to treat cataplexy, sudden episodes of muscle weakness, in adults with narcolepsy. The drug belongs to a class known as H3 receptor antagonists and works by regulating neurotransmitters involved in sleep-wake cycles. The company stated that the approved product is bioequivalent to Wakix, as per the approved labeling by the U.S. regulator. The tablets will be manufactured at Lupin's facility in Nagpur, India. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025. The counter rose 0.62% to Rs 2,346.25 on the BSE. Powered by Capital Market - Live